Insilico Medicine and Takeda sign AI drug discovery collaboration
Illustration (decorative, not data).Summary
Insilico will use its Pharma.AI platform to discover molecules for Takeda that meet pre-agreed scientific and early-development criteria; Takeda is responsible for clinical validation and receives exclusive global development, manufacturing and commercialization rights to the selected molecules. The release does not limit therapeutic areas, saying only that it covers Takeda's therapeutic areas (Takeda's core areas include gastroenterology and inflammation, rare diseases, oncology, neuroscience and vaccines). Insilico is one of the few companies with an AI-discovered molecule in Phase 2; this deal shows big pharma–AI partnerships moving from “platform validation” to routine pay-per-program business.
Deal terms, as disclosed
Project initiation fee, near-term payments and milestones of ~$60M + later success milestones (~$600M total) + tiered royalties.
Summary of public disclosures, not investment advice. Amounts are as announced; milestone payments are contingent and may never be paid.
Related same deal type
- Novartis takes global rights to Abogen's in vivo mRNA T-cell engager ABO2203Oct 2026
- Simcere Zaiming licenses CD79a×CD19×CD3 trispecific SIM0660 to RocheSep 2026
- Haisco immunology asset goes into ARCH-founded NewCo SentiveraAug 2026
- J&J locks up Sail Biomedicines' in vivo CAR-T with an equity stake and an acquisition optionJul 2026
Asset owners and investors: write to bd@inlightbio.com. Newsletter and report questions: contact@inlightbio.com.